Stock 6893 HIN SANG GROUP (INTERNATIONAL) HOLDING CO. LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Hin Sang Group (International) Holding Co. Ltd.

Equities

6893

KYG4590V1023

Pharmaceuticals

Market Closed - Hong Kong S.E.
Other stock markets
 04:08:20 2024-04-26 am EDT 		5-day change 1st Jan Change
0.31 HKD 0.00% Intraday chart for Hin Sang Group (International) Holding Co. Ltd. -3.12% -7.46%
Feb. 19 Hin Sang Group (International) Holding Co. Ltd. Announces Change of Company Secretary, Effective 19 February 2024 CI
2023 Hin Sang Group Narrows Fiscal H1 Loss MT

Valuation

Fiscal Period: March 2018 2019 2020 2021 2022 2023
Capitalization 1 1,443 1,094 797 589.6 316.6 425.8
Enterprise Value (EV) 1 1,248 1,160 1,043 914.9 619.5 731.3
P/E ratio 2,722 x 234 x -40.3 x -18.4 x -26.6 x -8.6 x
Yield 1.52% 1% - - - -
Capitalization / Revenue 7.66 x 5.95 x 4.52 x 4.94 x 2.63 x 5.23 x
EV / Revenue 6.62 x 6.3 x 5.92 x 7.66 x 5.14 x 8.98 x
EV / EBITDA 74.2 x 89.6 x 79.3 x -50.1 x -182 x -28.2 x
EV / FCF -141 x -5.36 x -7.1 x -21 x 29.1 x -63.8 x
FCF Yield -0.71% -18.6% -14.1% -4.76% 3.43% -1.57%
Price to Book 1.54 x 2.28 x 2.4 x 1.85 x 1.05 x 1.78 x
Nbr of stocks (in thousands) 1,093,508 1,093,796 1,091,796 1,091,796 1,091,796 1,091,796
Reference price 2 1.320 1.000 0.7300 0.5400 0.2900 0.3900
Announcement Date 7/27/18 7/30/19 7/30/20 7/30/21 7/28/22 7/28/23
1HKD in Million2HKD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: March 2018 2019 2020 2021 2022 2023
Net sales 1 188.6 184 176.2 119.4 120.5 81.46
EBITDA 1 16.83 12.95 13.15 -18.27 -3.396 -25.97
EBIT 1 6.239 1.589 3.759 -29.18 -15.83 -36.82
Operating Margin 3.31% 0.86% 2.13% -24.43% -13.13% -45.2%
Earnings before Tax (EBT) 1 1.061 -7.513 -28.63 -36.67 -11.42 -49.22
Net income 1 0.53 4.668 -19.79 -31.95 -11.91 -49.49
Net margin 0.28% 2.54% -11.23% -26.75% -9.88% -60.75%
EPS 2 0.000485 0.004268 -0.0181 -0.0293 -0.0109 -0.0453
Free Cash Flow 1 -8.838 -216.2 -147 -43.53 21.26 -11.47
FCF margin -4.69% -117.51% -83.4% -36.45% 17.63% -14.08%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share 2 0.0200 0.0100 - - - -
Announcement Date 7/27/18 7/30/19 7/30/20 7/30/21 7/28/22 7/28/23
1HKD in Million2HKD
Estimates

Balance Sheet Analysis

Fiscal Period: March 2018 2019 2020 2021 2022 2023
Net Debt 1 - 65.9 246 325 303 305
Net Cash position 1 195 - - - - -
Leverage (Debt/EBITDA) - 5.087 x 18.71 x -17.8 x -89.18 x -11.76 x
Free Cash Flow 1 -8.84 -216 -147 -43.5 21.3 -11.5
ROE (net income / shareholders' equity) -0.78% -1.56% -7.64% -11.2% -4.22% -18.2%
ROA (Net income/ Total Assets) 0.41% 0.12% 0.36% -2.71% -1.41% -3.51%
Assets 1 130.3 3,956 -5,477 1,180 845.9 1,411
Book Value Per Share 2 0.8600 0.4400 0.3000 0.2900 0.2800 0.2200
Cash Flow per Share 2 0.1700 0.0600 0.0100 0.0100 0.0100 0.0100
Capex 1 18.7 237 163 63.8 0.34 4.2
Capex / Sales 9.91% 129.01% 92.42% 53.43% 0.28% 5.15%
Announcement Date 7/27/18 7/30/19 7/30/20 7/30/21 7/28/22 7/28/23
1HKD in Million2HKD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Pharmaceuticals

1st Jan change Capi.
HIN SANG GROUP (INTERNATIONAL) HOLDING CO. LTD. Stock Hin Sang Group (International) Holding Co. Ltd.
-7.46% 43.24M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.83% 661B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+27.00% 566B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.76% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 332B
ABBVIE INC. Stock AbbVie Inc.
+3.00% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.09% 231B
NOVARTIS AG Stock Novartis AG
+5.46% 200B
ROCHE HOLDING AG Stock Roche Holding AG
-9.61% 195B
AMGEN INC. Stock Amgen Inc.
-6.26% 145B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 6893 Stock
  4. Financials Hin Sang Group (International) Holding Co. Ltd.